A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer

NCT00488722 · clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tianjin Medical University